Roman Yelensky BA, MS, PhD

Roman Yelensky serves as Executive Vice President of Sequencing and Bioinformatics, responsible for therapeutic neo-antigen discovery and selection. Dr. Yelensky joined Gritstone from Foundation Medicine (NASDAQ: FMI), where he was Vice President of Biomarker and Companion Diagnostic Development. Yelensky, who joined Foundation Medicine at its inception, co-led sequence data analysis for FoundationOneTM and led validation studies supporting clinical laboratory accreditation.

While at Foundation, Yelensky contributed regularly to key national initiatives on the clinical implementation and oversight of next-generation sequencing (NGS), leading the diagnostic implementation of Lung-MAP, a first-of-its-kind NCI-sponsored trial matching lung cancer patients to investigational treatments using comprehensive genomic testing. Prior to joining Foundation Medicine, Yelensky was a Senior Scientist in Biomarker Development at Novartis. He holds a Ph.D. in Bioinformatics and Integrative Genomics from the Harvard-MIT Division of Health Sciences and Technology, with thesis research at the Broad Institute, and an MS in Computer Science from Stanford University. He has co-authored more than 50 manuscripts on bioinformatics, statistical genetics, NGS biomarker and assay development, and cancer genomics.